drugset / Trial / NCT06380907
A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical gel (A Human VH IL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis
Timeline
- Start
- 2024-05-22
- Primary completion
- 2026-02-28
- Completion
- 2026-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ZL-1102 | Protein / enzyme biologic | 1 % | Topical |
| Comparator | ZL-1102 | Protein / enzyme biologic | 3 % | Topical |